Cerhum
The startup develops a 3D-printed bone graft made from bone-similar materials specifically designed for repairing facial deformities. This technology eliminates the need for autografts and non-regenerative materials, thereby reducing surgery times and enhancing patient comfort.
- Biotechnology
- Hardware
Funding
Raised to date
$4.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for repairing facial bone defects often involve autografts, which require a second surgical site and can lead to donor-site morbidity, or non-regenerative materials that may not fully integrate with the patient's own bone. These approaches can result in longer surgery times, increased patient discomfort, and suboptimal aesthetic outcomes.
Solution
Cerhum provides MyBone, a line of patient-specific, 3D-printed bioceramic bone grafts designed for maxillofacial and reconstructive surgeries. These grafts are made from hydroxyapatite, a biocompatible material similar to natural bone, and feature a patented interconnected porous structure that promotes rapid vascularization and bone regeneration. By using virtual surgical planning and 3D printing, Cerhum creates grafts that precisely match the patient's anatomy, reducing the need for extensive intraoperative adjustments. The MyBone solution aims to improve surgical outcomes, reduce patient recovery times, and enhance aesthetic results compared to traditional bone grafting methods.
Target Audience
The primary target audience includes maxillofacial surgeons, plastic surgeons, and dental surgeons seeking advanced bone grafting solutions for facial reconstruction, trauma repair, and aesthetic enhancement.
Features
- Patient-specific design based on virtual surgical planning and 3D printing
- Biocompatible hydroxyapatite material that mimics natural bone composition
- Patented interconnected porous structure optimized for vascularization and osteointegration
- Reduced surgery times and infection risks compared to autografts
- Improved aesthetic outcomes due to precise anatomical fit
- Biocompatibility validated through in vitro and preclinical studies
- Compressive strength close to trabecular bone